Business
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that it has been granted a 180 calendar day extension from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minim
About this update from Intensity Therapeutics, Inc.
[{"type":"text","content":"SHELTON, Conn., Dec. 5, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that it has been granted a 180 calendar day extension from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on Nasdaq (the "Minimum Bid Price Requirement"), following the expiration of the initial 180 calendar day period to regain compliance on December 3, 2025, which was initially granted on June 6, 2025. The Company now has until June 1, 2026 to meet the Minimum Bid Price Requirement set forth in Nasdaq Listing Rule 5550(a)(2).","length":1039,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Intensity Therapeutics Inc.)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Intensity Therapeutics Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":101,"url":"https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zdViy5pzlzPB_LdO71ooeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8","width":400,"height":101}},"href":"https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The notification has no immediate effect on the listing or trading of the Company's shares of common stock, which will continue to trade on the Nasdaq Capital Market under the symbol "INTS." To regain compliance with the Rule, the Company must maintain a closing bid price of at least $1.00 per share for a minimum of ten (10) consecutive business days on or prior to the 180-day extension period, or June 1, 2026. The Company intends to actively monitor the closing bid price of its common stock between now and the end of the extension period and intends to take all appr...